madman
Super Moderator
Estrogen in its various forms has long been used as a primary and secondary means of managing prostate cancer. Primarily it can be used in place of an LHRH ADT drug. In its secondary capacity, it can be employed in addition to an LHRH drug to help men cope with side effects arising from lack of estrogen caused by the LHRH drug. These side effects include hot flashes and weakening bone density.
Today Estradiol (E2) is considered to be a safe treatment when used as a skin patch or gel versus its original application in pill form that carried significant cardiovascular risks.
The foremost peer expert on the use of estrogen to manage prostate cancer is Richard Wassersug, Ph.D, author of "Androgen Deprivation Therapy: An Essential Guide for Prostate Cancer Patients and Their Loved Ones" that is now in its 3rd Edition https://connect.springerpub.com/conte.... Richard is also an AnCan Advisory Board Member.
In this 60 +minute discussion, Dr. Wassersug talks with two patients about using estradiol. One has used for primary control for 17 years, and the other just started using an Estradiol patch to control side effects alone. He is also joined by AnCan advanced PCa peer Moderators, Dr. John Antonucci and Rick Davis.
Rechallenging advanced disease with enzalutamide after Pluvicto is mentioned towards the end. Dr. Wassersug has since clarified that he favors rechallenging advanced disease with previous therapies after some form of radiation based on the abscopal effect. The use of enzalutamide in this context is not based on trial evidence.
AnCan asks that you first read Richard Wassersug's book before reaching out to him. AND... Dr. Wassersug urges you to spend as much time exercising today as you have taken to watch this video!
